{
    "fund_name": "iShares NASDAQ US Biotechnology UCITS",
    "type": "ETF",
    "ucits": true,
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The iShares NASDAQ US Biotechnology UCITS ETF is a physically replicated fund that aims to track the NASDAQ Biotechnology Index by holding the underlying equity securities. The KIID and factsheet indicate that the fund uses physical replication and does not employ leverage, inverse strategies, or synthetic replication. While the fund may use financial derivative instruments (FDIs) for efficient portfolio management, this does not inherently make the fund complex under MiFID II, as the derivatives are not used extensively or in a way that creates significant additional risk. The fund's risk profile is transparent, and the underlying assets are liquid and easily understandable. The fund is UCITS-compliant, which further supports its classification as non-complex.",
    "confidence": 95,
    "risk_level": 6,
    "counter_argument": "Some might argue that the use of derivatives for portfolio management could introduce complexity. However, the derivatives are used in a limited and controlled manner, primarily for hedging and reducing transaction costs, which does not materially alter the fund's risk profile or make it difficult for retail investors to understand. The fund's physical replication method and straightforward investment strategy outweigh this concern."
}